People · Operator
Named in public records as an officer, director or promoter · active 2012–2022 · Biotech / Pharma, Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| PharmaCann Inc. | — | Biotech / Pharma | Series D+ | $509.0M | $413.5M | 2022 |
| Savara Inc. | — | Pharmaceuticals | Series B | $84.3M | $702.9M | 2012 |
| LivWell Holdings, Inc. | — | Other | Series C | $59.2M | $440.3M | 2019 |
John Lord at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Lord on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Yuri Pikover | 1 | 9 |
| John McCarthy | 1 | 6 |
| James Barry | 1 | 5 |
| Patrick Barry | 1 | 4 |
| John Leja | 1 | 4 |
| Robert Neville | 1 | 2 |
| Nevan Elam | 1 | 2 |
| Teddy Scott | 1 | 2 |
| Richard Benkendorf | 1 | 2 |
| Rick Hawkins | 1 | 2 |
| Cory Berkland | 1 | 2 |
| Shirley Gee | 1 | 2 |
| Richard Hawkins | 1 | 2 |
| Daniel Roth | 1 | 2 |
| Taneli Jouhikainen | 1 | 2 |
| Joseph S. McCracken | 1 | 2 |
| Curt Bilby | 1 | 2 |
| John A Leja | 1 | 1 |
| Christina Leja | 1 | 1 |
| George Laurence | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.